{"id":"vrdn-003","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Upper respiratory tract infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VRDN-003 binds to TSI, the pathogenic autoantibody responsible for thyroid overstimulation in Graves' disease, thereby blocking its interaction with the TSH receptor. By neutralizing TSI, the drug reduces thyroid hormone overproduction and associated hyperthyroid symptoms. This mechanism addresses the underlying autoimmune pathology rather than just symptom management.","oneSentence":"VRDN-003 is a monoclonal antibody that targets and inhibits thyroid-stimulating immunoglobulin (TSI) to reduce autoimmune thyroid activation in Graves' disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:55.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Graves' disease (hyperthyroidism)"}]},"trialDetails":[{"nctId":"NCT07155668","phase":"PHASE3","title":"A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2025-07-01","conditions":"Thyroid Eye Disease","enrollment":87},{"nctId":"NCT07211776","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease","status":"RECRUITING","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2025-12-05","conditions":"Thyroid Eye Disease (TED)","enrollment":99},{"nctId":"NCT06812325","phase":"PHASE3","title":"A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2025-02-03","conditions":"Thyroid Eye Disease (TED)","enrollment":321},{"nctId":"NCT06625411","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2024-08-27","conditions":"Thyroid Eye Disease","enrollment":117},{"nctId":"NCT06625398","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Viridian Therapeutics, Inc.","startDate":"2024-08-27","conditions":"Thyroid Eye Disease","enrollment":195}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VRDN-003","genericName":"VRDN-003","companyName":"Viridian Therapeutics, Inc.","companyId":"viridian-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VRDN-003 is a small molecule being studied in a clinical trial for the treatment of Thyroid Eye Disease (TED). The trial, NCT07155668, is evaluating the safety, tolerability, and pharmacokinetics of VRDN-003 in participants with TED.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}